AMY NYDAM: Open Payments
NPI 1477070852 · LEXINGTON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,573 in 135 payments from 19 companies in 2025. Trend: 2023 $1,420 · 2024 $1,873 · 2025 $2,573
Food & beverage: $2,496Education: $77
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 33 | $717 |
| Janssen Biotech, Inc. | 28 | $389 |
| Phathom Pharmaceuticals, Inc. | 18 | $324 |
| Ardelyx, Inc. | 13 | $239 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 9 | $143 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $113 |
| Lilly USA, LLC | 5 | $101 |
| GENZYME CORPORATION | 4 | $100 |
| Ipsen Biopharmaceuticals, Inc | 4 | $81 |
| QOL Medical, LLC | 3 | $75 |
Products named: TREMFYA, VOQUEZNA, RINVOQ, LINZESS, IBSRELA, DUPIXENT, MAVYRET, XIFAXAN.
Industry payments across KY — which companies pay providers there.
